Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-06-28
2005-06-28
Travers, Russell (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S309000
Reexamination Certificate
active
06911454
ABSTRACT:
The specification discloses a method for enhancing the inhibiting action of drugs against multidrug resistant cells, apparently by reversing or inhibiting the glycoprotein “pumps” associated with such cells.
REFERENCES:
patent: 4761417 (1988-08-01), Maroko
patent: 5079363 (1992-01-01), Bouisset et al.
patent: 5086059 (1992-02-01), Ardecky et al.
patent: 9218131 (1992-10-01), None
Liao 93CA: 197657u 1980.
Fuska 104 CA: 84939-q 1985.
Dept of Pharmacology et al, Chinese Medical Journal 93(3): pp 193-198 1979.
Fang et al. “A new calcium Antagonist of Chinese Medical Oxygen Tetrandrine” Journal of Hypertension 1986 4(Supp 6) 5150-5152.
Qian et al Hypotensive Activity of Tetrandrine in Pos Pharmacology 26:187-197 (1983).
Kawashima et al General Pharmacology vol. 21 #3 pp 343-347 1990.
Grolla et al Cornea Chemotherapy Reports Part 3 vol. 5 #1 Sep. 1974 pp 79-85.
Griffiths, CA 99:133454s 1983.
Akiyama, CA 108:161022y 1988.
Kuroda, CA 86:65337k 1977.
Mitscher, CA 75:59821v 1971.
Merck Index 10th Ed # 2136 & 9050.
Merck Index 10Ed 9056, 2136.
CA # 86 202f Cerny et al 1977.
CA # 86 65337k Kureida et al 1977.
Merck Index 10th Ed #3436, 9784, 9788.
Fournel et al 110:CA: 132057 1988.
Fournel et al 110 CA 132058z 1988.
“Protein Kinase C Phosphorylates P-Glycoprotein in Multidrug Resistant Human KB Carcinoma Cells,” by T.C. Chambers et al., The Journal of Biological Chemistry, vol. 265, No. 13, May 5, 1990, pp. 7679-7686.
“The Dependence of the Tuberculostatic Activity of Bis Benzyl Iso Quinoline Alkaloids on their Structure,” Database Biosis Biosciences Information Service, & Farmatsiya, vol. 27, No. 2, 1978, pp. 23-26, O.N. Tolkachev et al. (Abstract).
“Chemotherapeutic Properties of the Alkaloid Tetrandrine in Experimental Tuberculosis,” Database Chemabs Chemical Abstracts Service, & Farmakol. Toksikol., vol. 36, No. 1, 1973, pp. 74-78, S.A., Vichkanova et al. (Abstract), CA:78(17) 106079h.
“Tuberculostatic Activity of Preparations from Plants,” by S.A. Vichkanova et al., Database Chemabs, Chemical Abstracts Service, & Fitontsidy, Mater. Soveshch., 6th Meeting, 1969, pp. 90-94. (abstract). CA78(11):66905R.
“Effects of Methoxyadiantifoline on Coronary Circulation and Contractility of Coronary Strips,” by Jufang Jia et al., Database Chemabs, Chemical Abstracts Service, vol. 2, No. 3, 1988, pp. 193-196, (Abstract). CA109(19):163208g.
“Interaction of Bisbenzylisoquinoline Alkaloids with Alveolar Macrophages,” by J.Y.C. Ma et al., Faseb J., vol. 4, No. 7, 1990, p. A2116, (Abstract).
“Effects of Bisbenzylisoquinoline Alkaloids on Alveolar Macrophages: Correlation Between Binding Affinity, Inhibitory Potency, and Antifibrotic Potential,” by V. Castranova et al., Toxicology and Applied Pharmacology, vol. 108, No. 2, 1991, pp. 242-252.
“Selective Antimalarial Activity of Tetrandrine Against Chloroquine Resistant Plasmodium Falciparum,” Biophysical and Biochemical Research Communications, vol. 159, No. 1, Feb. 28, 1989, pp. 242-248.
“The Potentiating Action of Tetrandrine in Combination with Chloroquine or Qinghaosu Against Chloroquine-Sensitive and Resistant Falciparum Malaria,” Biochemical and Biophysical Research Communications, vol. 165, No. 2, Dec. 15, 1989, pp. 758-765. By Applicant.
“In Vitro Activity on Epimastigotes of Three Typified Strains of Trypanosoma Cruzi,” Journal of Ethnopharmacology, 24 (1988) 337-343, A. Fournet et al.
“In Vitro Activity on the Promastigotes of Three Strains of Leishmania,” Journal of Ethnopharmacology, 24 (1988) 327-335, A. Fournet et al.
Phosphorylation of the Mr170,000 to 180,000 Glycoprotein Specific to Multidrug-resistant Tumor Cells: Effects of Verapamil, Trifluorperazine, and Phorbol Esters1, by Hamada et al., Cancer Research 47, 2860-2865, Jun. 1, 1987.
Overcoming Multidrug Resistance In Malaria, by Swyers, Research Resources Reporter, Feb. 1990, vol. XIV, No. 2.
9056. Tetrandrine, Merck Index, No. 9061, p. 1321.
84:159552n, 1-Pharmacodynamics, vol. 84, 1976, p. 17.
55716e, Chemical Abstracts, vol. 72, 1970, p. 464.
86:202t, Chemical Abstracts, vol. 86, 1977, p. 16.
106:135e, Chemical Abstracts, vol. 106, 1987, pp. 127-128.
108:87627e, 1-Pharmacology, vol. 108, 1988, p. 23.
110:132058z, Chemical Abstracts, vol. 110, 1989, p. 416.
What is Synergy?, by Berenbaum, The American Society for Pharmacology and Experimental Therapeutics, vol. 1989, No. 41, pp. 93-141.
Manual of Pharmacologic Calculations, by Tallarida et al., pp. 54-113.
3H-Azidopine Photoaffinity Labeling of High Molecular Weight Proteins in Chloroquine Resistant Falciparum Malaria, by Ye et al., Biochemical and Biophysical Research Communications, vol. 162, No. 2, 1989, Jul. 31, 1989, pp. 809-813.
Genetic mapping of the chloroquine-resistance locus on Plasmodium falciparum chromosome 7, by Wellems et al., Proc. Natl. Acad. Sci. vol. 88, pp. 3382-3386, Apr. 1991.
Amplification of a Gene Related to Mammalian mdr Genes in Drug-Resistant Plasmodium falciparum, by Wilson et al., Science, vol. 24, pp. 1184-1186, 1989.
The Potentiating Action of Tetrandrine in Combination with Chloroquine or Qinghaosu Against Chloroquine-Sensitive and Resistant Falciparum Malaria, by Ye et al., Biochemical and Biophysical Research Communications, vol. 165, No. 2, 1989, Dec. 15, 1989, pp. 758-765.
Amplification of the Multidrug Resistance Gene in Some Chloroquine-Resistant Isolates ofP. falciparum,by Foote et al., Cell, vol. 57, 921-930, Jun. 16, 1989.
Merck Index, 8th ed., p. 142.
6387. Nifurtimox, Merck Index, p. 938.
Mechanism of multidrug resistance, by Bradley et al., Biochimica et Biophysica Acta, 948 (1988) 87-128.
Immunohistochemical Analysis of P-glycoprotein Expression Correlated with Chemotherapy Resistance in Locally Advanced Breast Cancer, by Ro et al., Original Contributions, pp. 787-791.
Detection of Multidrug Resistance Associated P-170 Glycoprotein in Previously Untreated Non Small Cell Lung Cancer, by Scagliotti et al., Anticancer Research II:2207-2210 (1991).
Clinical Relevance of Immunohistochemical Detection of Multidrug Resistance P-glycoprotein in Breast Carcinoma, Reports, vol. 83, No. 2, Jan. 16, 1991, pp. 111-116.
Clinical Significance of Multidrug Resistance P-glycoprotein Expression on Acute Nonlymphoblastic Leukemia Cells at Diagnosis, by Campos et al., Blood, vol. 79, No. 2 (Jan. 15), 1992, pp. 473-476.
Detection of Multidrug Resistance Markers, P-glycoprotein and mdrl mRNA, in Human Leukemia Cells, by Tsurno et al., Jpn. J. Cancer Res. (Gann), 78, 1415-1419, Dec. 1987.
Multidrug (Pleiotropic) Resistance in the Human Sarcoma Cell Line MES-SA, by Sikic, et al., Chapter 3, pp. 37-47.
Vichkanova, S.A.; Makarova, L.V.; Solov'eva, L.F., “Chemotherapeutic Properties of the Alkaloid”—Abstract CA78(17) 106079h 1973.
Vichkanova, S.A.; Makarova, L.V.; Gordeikina, N.I., “Tuberculostatic Activity of Preparations from Plants”—Abstract CA78(11)66905R 1972.
Tolkachev O.N.; Vichkanova, S.A.; Makarova L.V.; Naidovich L.P., “The Dependence of the Tuberculostatic Activity of Bis Benzyl Iso Quinoline Alkoids on their Structure”—Abstract 79:166230 Biosis 1979.
Cancer Biologics of America, Inc.
Price Heneveld Cooper DeWitt & Litton
Travers Russell
LandOfFree
Method for potentiating primary drugs in treating multidrug... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for potentiating primary drugs in treating multidrug..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for potentiating primary drugs in treating multidrug... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3488817